By using our site you accept the terms of our cookie policy

Keryx Biopharmaceuticals, Inc. Misled Shareholders

October 12, 2016

Image

Keryx Biopharmaceuticals, Inc. Misled Shareholders According to a Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Keryx Biopharmaceuticals, Inc. in the U.S. District Court for the District of Massachusetts.

The complaint is brought on behalf of all purchasers of Keryx securities between September 2, 2013 and August 1, 2016, for alleged violations of the Securities Exchange Act of 1934 by Keryx's officers and directors. Keryx is a biopharmaceutical company that focuses on providing therapies for patients with renal disease in the United States. Its product, Auryxia, is an oral, absorbable iron-based compound designed to control serum phosphorous levels in patients with chronic kidney disease on dialysis.

View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/keryx-biopharmaceuticals-inc-sept-2016

Keryx Accused of Concealing Production Difficulties Surrounding Its Drug Product

According to the complaint, throughout the class period, Keryx officials schemed to mislead shareholders into believing that the company would contract with multiple manufacturers to produce Auryxia. For example, Keryx repeatedly referenced "third party manufacturers" and "contract manufacturers" in its public filings. In so doing, the company allegedly concealed the true risks associated with the manufacturing and supply of Auryxia because Keryx contracted with only a single manufacturer to produce its only marketed drug.

The complaint further alleges that Keryx officials failed to disclose: (1) that the company lacked adequate inventory controls; (2) that at some point during the class period, Keryx officials became aware but did not disclose that its contract manufacturer was experiencing production difficulties; and (3) that these production difficulties would deplete Keryx's Auryxia inventory. On August 1, 2016, Keryx revealed that the company would halt the distribution of Auryxia until at least October 2016 due to production difficulties on the part of its only contract manufacturer, and that Keryx was withdrawing its financial guidance for 2016. On this news, Keryx stock fell $2.64 per share, or 35.8%, to close at $4.72 per share on August 1, 2016.

Keryx Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, [email protected], or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact Us

+44 (0) 203 725 6841